Search Results

1 - 10 of 42 items :

  • Pediatrics and Juvenile Medicine x
Clear All
The prognostic value of mean platelet volume in cancer patients

-affecting children, unfortunately, approximately 10% of young patients never achieve complete remission [ 32 , 33 ]. In the study of Huang et al. [ 30 ], PLT, MPV, and PCT levels were found to be lower in the ALL group than in the normal and ALL complete remission induced groups ( p < 0.05). Although in other research, the MPV was larger in patients with leukemia (mean ± SD: 8.615 ± 1.59 fL) than in controls group (mean ± SD: 8.355 ± 1.11 fL) at diagnosis, but it was statistically not significant between the two groups ( p = 0.36). Authors suggested that the cause of this was

Open access
Infectious complications in children and adults with hematological malignancies

.3%) as proven/probable IFD, and 39 (6.6%) as VI. Similarly, in 41 (67.2%) patients with rAML disease, 99 EIC were found (2.4 IC per patient), including BI in 78 (78.8%), probable IFD in 14 (14.1%), and VI in 7 (7.1%) cases ( p =0.5). Gram-negative strains were predominant, including multidrug-resistant strains in half of the cases. Characteristics of IFD and VI were comparable for iAML and rAML. Survival of infectious complications . Overall, in iAML group, 10 out of 250 (4.0%) patients died due to EIC: IFD contributed to three deaths, whereas BSI caused by

Open access
Diagnosis and management of complications of chronic lymphocytic leukemia/small lymphocytic lymphoma

, et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 2010;116:4771-6. 20736453 10.1182/blood-2010-05-286500 Moreno C Hodgson K Ferrer G et al Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance Blood 2010 116 4771 6 [61] Hallek M, Cheson BD, Catovsky D, et al. CLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018

Open access
Wyzwania wczesnej diagnostyki szpiczaka plazmocytowego – algorytm diagnostyczny

D, Smith A, Appleton S, et al. Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population‐based study. Br J Haematol 2017;177(1):67–71. 28146275 10.1111/bjh.14513 Howell D Smith A Appleton S et al Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population‐based study Br J Haematol 2017 177 1 67 71 [6] Lyratzopoulos G, Saunders Cl, Abel GA, et al. The relative length of the patient and the primary care interval in patients with 28 common and

Open access
Rzadkie postacie chłoniaków T-komórkowych – aktualne postępowanie

/mdv201 D’Amore F Galuard P Trupmer L et al Peripheral T cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2015 26 Suppl 5:v 108 15 [4] MD Anderson Cancer Center. Peripheral T-cell Lymphomas (PTCL) practice algorithm. 2017. MD Anderson Cancer Center. Peripheral T-cell Lymphomas (PTCL) practice algorithm 2017 [5] Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood 2011;117:6756–67. 21493798 10.1182/blood-2010-05-231548 Foss FM Zinzani PL Vose JM et al

Open access
Postępowanie u pacjentek z nowotworem mieloproliferacyjnym BCR-ABL ujemnym w ciąży

otrzymywały LMWH ryzyko VTE w trakcie ciąży wynosiło 2,5% (95% CI, 1,3-4,3), a w okresie połogu 4,4% (95% CI, 1,2-9,5). Uważa się, że ryzyko VTE u zdrowych ciężarnych wynosi 0,1% (5-12/10 000 ciąż) i 0,05% w okresie połogu (3-7/10 000) [ 8 , 9 ]. Przyjmuje się, że korzyść z profilaktyki LMWH odnoszą kobiety, u których ryzyko VTE wynosi ≥ 3%. Autorzy zalecają zatem profilaktykę LMWH w okresie połogu u wszystkich pacjentek z MPN bez przeciwskazań do tej terapii. Chore na MPN narażone są również na większe ryzyko krwawień. W obserwowanej grupie odnotowano 12 epizodów

Open access
Chłoniak z komórek płaszcza – rola terapii celowanych

. Piśmiennictwo/References [1] Martin P, Ghione P, Dreyling M. Mantle cell lymphoma – Current standards of care and future directions. Cancer Treat Rev 2017;58:51-60. 10.1016/j.ctrv.2017.05.008 28651117 Martin P Ghione P Dreyling M Mantle cell lymphoma – Current standards of care and future directions Cancer Treat Rev 2017 58 51 60 [2] Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk- stratification, and clinical management. Am J Hematol 2017;92:806- 13. 28699667 10.1002/ajh.24797 Vose JM Mantle cell lymphoma: 2017 update on

Open access
Metody cytogenetyki molekularnej w różnicowaniu agresywnych B-NHL

-cell lymphomas resembling Burkitt lymphoma. Blood 2014;123(8):1187–98. 10.1182/blood-2013-06-507996 24398325 Salaverria I Martin-Guerrero I Wagener R et al A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma Blood 2014 123 8 1187 98 [11] Ferreiro JF, Morscio J, Dierickx D, et al. Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern. Haematologica 2015;100(7):275–79. 10.3324/haematol.2015

Open access
ABC of viral infections in hematology: focus on herpesviruses

% at 1y [8] 3% (1% MFD, up to 11% MMUD/haplo) [7] 0.5% (BM/PB) 8.3%–11.6% (CBT) [14,16] 30%–60% (without prophylaxis) [5] MFD (matched family donor); MMUD (mismatched unrelated donor); CBT (cord blood transplantation); BM (bone marrow); PB (peripheral blood) The highest risk of CMV recurrence and CMV disease is reported for HCT CMV-seropositive recipients (R), regardless on donor (D) serostatus. The odds ratio for CMV recurrence is higher for R+ vs R- CMV-serostatus transplants (odds ratio: OR=8.0), D-/R+ vs D+/ R+ CMV-serostatus transplants

Open access
Early Results of Microsurgical Treatment of Acromegaly

persistent disease Biochemical control Persistent disease Females+ 26/59 (44%) 8/14 (57%) P=0,39 Fisher Exact Test Age mean±satandard deviation 43,03±16,2 36,68±9,42 P=0,24 Student T test Cavernouse sinus invasión 6/59 (10%) 17/22(77%) p<0,001 Fisher Exact Test Microadenoma 28/59 (47%) 0/22 (0%) p<0,001 Fisher Exact Test Preoperative GH median±interqartile range (mU/ml) + 18,35±16,2 8,5±6,8 p<0,05 Mac Niemann Preoperative IGF-1 median±interqartile range (ng/ml) + 842±277 805±460 P=0

Open access